Alopecia areata is a heterogeneous disease characterized by nonscarring hair loss. It affects 1-2% of the population of both genders and occurs in all age groups. According to the recent studies, helper T cells 1, helper T cells 2, helper T cells 17, and regulatory T cells may be the main possible initiators of alopecia areata. The purpose of the study was to determine the concentrations of serum interleukin-17A, interleukin-10 and interleukin-2 in patients with alopecia areata, and to study the relationship between their levels before and after treatment with platelet-rich plasma. Materials and methods. The study involved 37 patients with alopecia areata aged (35.7±8.9) years and 30 people of the control group aged (37.4±7.9) years. People with alopecia areata were injected with platelet-rich plasma. For this, immediately before administration, venous blood was taken from the patients from the cubital vein into a special tube for the preparation of platelet-rich plasma. Platelet-rich plasma was injected into the lesions at the rate of 0.2 ml/cm2 using an insulin syringe and a 30 G needle, once every 2 weeks for 16 weeks. The patients were examined before the treatment and in 3, 6 and 17 months. The concentrations of interleukin-17A, interleukin-2 and interleukin-10 were determined in blood serum before treatment and after 3, 6 and 17 months of observation by the Sandwich-ELISA method (enzyme-linked immunosorbent assay). Interleukin-17A, interleukin-2 and interleukin-10 in the blood serum in the control group were also determined. The software program SPSS 22.0 was used for the statistical analysis. The normality distribution was tested by Shapiro-Wilk’s method. Independent Student’s t-test for unpaired samples was used to compare mean values between groups. The p-value < 0.05 was considered significant. Results and discussion. The results obtained in our study showed that the concentrations of the pro-inflammatory cytokines interleukin-17A and interleukin-2 were significantly higher in persons with alopecia areata before treatment. After 17 months of therapy with platelet-rich plasma, serum interleukin-17A and interleukin-2 levels approached the control level. Conclusion. There was no difference in the concentration of anti-inflammatory interleukin-10 between patients with alopecia areata and healthy people. In the course of treatment, the concentration of interleukin-10 increased after 3 and 17 months of therapy

Keywords: alopecia areata, interleukin-17A, interleukin-2, interleukin-10, platelet-rich plasma

Full text: PDF (Ukr) 277K

1. Safavi KH, Muller SA, Suman VJ, Moshell AN, Melton LJ 3rd. Incidence of alopecia areata in Olmsted Country, Minnesota, 1975 through 1989. Mayo Clin Proc. 1995; 70(7): 628-633. https://doi.org/10.4065/70.7.628
2. Barahmani N, Lopez A, Babu D, Hernandez M, Donley SE, Duvic M. Serum T helper 1 cytokine levels are greater in patients with alopecia areata regardless of severity or atopy. Clin Exp Dermatol. 2010; 35: 409-416. https://doi.org/10.1111/j.1365-2230.2009.03523.x
3. Gilhar A, Kalish RS. Alopecia areata: a tissue specific autoimmune disease of the hair follicle. Autoimmun Rev. 2006; 5: 64-69. https://doi.org/10.1016/j.autrev.2005.07.001
4. Harpaz I, Abutbul S, Nemirovsky A, Gal R, Cohen H, Monsonego A. Chronic exposure to stress predisposes to higher autoimmune susceptibility in C57BL/6 mice: glucocorticoids as a double-edged sword. Eur J Immunol. 2013; 43: 758-769. https://doi.org/10.1002/eji.201242613
5. Gilhar A, Landau M, Assy B, Shalaginov R, Serafimovich S, Kalish RS. Mediation of alopecia areata by cooperation between CD4+ and CD8+ T lymphocytes: transfer to human scalp explants on Prkdc(scid) mice. Arch Dermatol. 2002; 138(7): 916-922. https://doi.org/10.1001/archderm.138.7.916
6. Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol. 2010; 10: 479-489. https://doi.org/10.1038/nri2800
7. Ito T, Tokura Y. The role of cytokines and chemokines in the T-cell-mediated autoimmune process in alopecia areata. Exp Dermatol. 2014; 23(11): 787-791. https://doi.org/10.1111/exd.12489
8. Messenger AG, McKillop J, Farrant P, McDonagh AJ, Sladden M. British Association of Dermatologists’ guidelines for the management of alopecia areata. Br J Dermatol. 2012; 166: 916-926. https://doi.org/10.1111/j.1365-2133.2012.10955.x
9. Olsen E, Hordinsky M, McDonald-Hull S, Price V, Roberts J, Shapiro J, et al. Alopecia areata investigational assessment guidelines. National Alopecia Areata Foundation. J Am Acad Dermatol. 1999; 40: 242-6. https://doi.org/10.1016/s0190-9622(99)70195-7
10. Rossi A, Muscianese M, Piraccini BM. Italian Guidelines in diagnosis and treatment of alopecia areata. Giornale Italiano di Dermatologia e Venereologia. 2019; 154(6): 609-23. https://doi.org/10.23736/S0392-0488.19.06458-7
11. Morsy H, Maher R, Negm D. Correlation between serum IL-17A level and SALT score in patients with alopecia areata before and after NB-UVB therapy. J Cosmet Dermatol. 2018; 00: 1-5. doi: 10.1111/jocd.12664
12. Tembhre MK, Sharma VK. T-helper and regulatory T-cell cytokines in the peripheral blood of patients with active alopecia areata. Br J Dermatol. 2013; 169(3): 543-548. https://doi.org/10.1111/bjd.12396
13. Atwa MA, Youssef N, Bayoumy NM. T-helper 17 cytokines (interleukins 17, 21, 22, and 6, and tumor necrosis factor-alpha) in patients with alopecia areata: association with clinical type and severity. Int J Dermatol. 2016; 55(6): 666-672. https://doi.org/10.1111/ijd.12808
14. El-Morsy EH, Eid AA, Ghoneim H, Al-Tameemi KA. Serum level of interleukin-17A in patients with alopecia areata and its relationship to age. Int J Dermatol. 2016; 55: 869-874. https://doi.org/10.1111/ijd.12994
15. Bayramgurler D, Demirsoy EO, Akturk AS, Kiran R. Narrowband ultraviolet B phototherapy for alopecia areata. Photodermatol Photoimmunol Photomed. 2011; 27: 325-327. https://doi.org/10.1111/j.1600-0781.2011.00612.x
16. Cantrell DA, Smith KA. The interleukin-2 T-cell system: a new cell growth model. Science. 1984; 224: 1312-6. https://doi.org/10.1126/science.6427923
17. Malek TR. The biology of interleukin-2. Annu Rev Immunol. 2008; 26: 453-79. https://doi.org/10.1146/annurev.immunol.26.021607.090357
18. Castela E, Le Duff F, Butori C, Ticchioni M, Hofman P, Bahadoran P, et al. Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata. JAMA Dermatol. 2014; 150(7): 748-51. https://doi.org/10.1001/jamadermatol.2014.504
19. Tabara K, Kozłowska M, Jędrowiak A, Bienias W, Kaszuba A. Serum concentrations of selected proinflammatory cytokines in children with alopecia areata. Advances in Dermatology and Allergology. 2019; 36(1): 63-69. https://doi.org/10.5114/ada.2019.82826
20. Valsecchi R, Imberti G, Martino D, Cainelli T. Alopecia areata and interleukin-2 receptor. Dermatology. 1992; 184: 126-8. https://doi.org/10.1159/000247519
21. Teraki Y, Imanishi K, Shiohara T. Cytokines in alopecia areata: contrasting cytokine profiles in localized form and extensive form (alopecia universalis). Acta Derm Venereol. 1996; 76: 421-3. https://doi.org/10.2340/0001555576421423
22. Trinchieri G. Interleukin-10 production by effector T cells: Th1 cells show self control. J Exp Med. 2007; 204(2): 239-243. https://doi.org/10.1084/jem.20070104
23. Zhyvytsya DH. Syrovatkovyi riven IL-10 ta IL-17 u khvorykh na VIL infektsiyu z tyazhkoyu imunosupresiyeyu [Serum level IL-10 and IL-17 in HIV patients with severe immunosuppression]. Infektsiyni khvoroby. 2015; 3: 13-15. [Ukrainian]. doi: 10.11603/1681-2727.2014.3.3919
24. Xinguo X. Effects of compound glycyrrhizin on serum IFN-γ, IL-10 and immunological index in patients with alopecia areata. Pharm Bioprocess. 2018; 6(1): 015-020.
25. Serbina IM. Tsitokinoposredovannye mekhanizmy formirovaniya gnezdnoy alopetsii [Cytokine-mediated mechanisms for the formation of the nest alopecia]. Nauchnye vedomosti. Seriya Meditsina. Farmatsiya. 2014; 24(195): 50-54. [Russian]